---
canonical_name: Fisetin
alternate_names: 3,3',4',7-Tetrahydroxyflavone, 7,3',4'-Trihydroxyflavonol, 5-Deoxyquercetin, Cognisetin, Novusetin
canonical_topic: Fisetin for Health & Longevity
short_topic_lc: fisetin
creation_date: 2026-0718-0420
creator_ai_fullname: Opus 4.8
---

# Fisetin for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/18/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** 3,3',4',7-Tetrahydroxyflavone, 7,3',4'-Trihydroxyflavonol, 5-Deoxyquercetin, Cognisetin, Novusetin

<!-- Author's note: This motivation section was written last, after the rest of the document was completed, so that it accurately reflects the full scope of the review. -->
  
## Motivation

Fisetin is a plant pigment belonging to a family of compounds called flavonoids, the same broad group that gives many fruits and vegetables their color and much of their protective activity. It occurs naturally in small amounts in strawberries, apples, persimmons, grapes, onions, and cucumbers. In the laboratory it has drawn attention as one of the more active members of a group of substances that appear to clear away worn-out, non-dividing cells that accumulate in the body with age.

For most of its history fisetin was viewed simply as one of many dietary antioxidants. That changed when researchers reported that giving it to aged mice reduced the burden of these worn-out cells, improved several measures of physical function, and modestly lengthened life. Because such cells are thought to drive much of the low-grade inflammation of aging, fisetin moved quickly from a minor dietary curiosity to a candidate longevity compound now being tested in people.

This review examines what is currently known about fisetin as it relates to healthy aging: how it is thought to work, what benefits and risks the evidence supports, how it is being used and studied, and where the science remains uncertain or contested.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

This section collects high-quality, high-level overviews of fisetin from prioritized experts and landmark primary research, suitable for readers who want an accessible entry point to the topic.

<!-- Author's note: A real-time web search and on-site searches were performed for each prioritized expert (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser) and for Life Extension, plus a PubMed search for landmark primary literature. Rhonda Patrick, Peter Attia, Life Extension, and Chris Kresser's platform carry directly relevant fisetin content; Andrew Huberman did not have substantial fisetin-specific material. Systematic reviews and meta-analyses were excluded from this section. -->

* [Fisetin inhibits senescence and slows down aging](https://podcast.foundmyfitness.com/news/s/4hhuqq/fisetin_inhibits_senescence_and_slows_down_aging) - Rhonda Patrick

  A concise expert summary from FoundMyFitness explaining why fisetin is considered a leading natural compound for clearing worn-out cells, with practical context on dietary sources such as apples and strawberries.

* [Targeting senescent cells for cognitive health](https://peterattiamd.com/senescent-cells-and-cognitive-health/) - Peter Attia

  A critical, balanced article on senolytics (drugs that clear worn-out cells) including fisetin, examining whether the enthusiasm around them for brain aging is justified by the current human evidence.

* [Fisetin: A Senolytic That Extends Life](https://www.lifeextension.com/magazine/2021/2/fisetin-senolytic-benefits) - Charles Wyatt

  A readable overview of fisetin's proposed longevity mechanisms and the bioavailability problem that has driven the development of enhanced-absorption formulations.

* [Fisetin is a senotherapeutic that extends health and lifespan](https://pubmed.ncbi.nlm.nih.gov/30279143/) - Yousefzadeh et al., 2018

  The landmark preclinical paper that identified fisetin as one of the most potent natural senolytics and reported extended median lifespan in aged mice; the origin of most current human interest.

* [What Do Phytochemicals Do for Your Health?](https://chriskresser.com/phytochemicals-and-their-role-in-health/) - Lindsay Christensen

  An accessible overview on Chris Kresser's platform that profiles fisetin among key dietary phytochemicals, framing it as a flavonoid found in strawberries, apples, and onions with emerging interest for cellular health and longevity through its effect on sirtuins.

Note: Independent web and on-site searches found no substantial fisetin-specific content from Andrew Huberman (hubermanlab.com); this expert is therefore not represented above.

  
## Grokipedia

<!-- Author's note: grokipedia.com was searched directly using the browser tool for "Fisetin". A dedicated, fact-checked article exists at grokipedia.com/page/Fisetin. -->

* [Fisetin](https://grokipedia.com/page/Fisetin)

  Grokipedia's fisetin article gives a structured, fact-checked overview spanning the compound's chemistry and natural occurrence, its biosynthesis and metabolism, its pharmacology, and the current research on its senolytic and healthspan applications.

  
## Examine

<!-- Author's note: examine.com was searched directly using the browser tool for "Fisetin". A dedicated supplement page exists at examine.com/supplements/fisetin/. -->

* [Fisetin](https://examine.com/supplements/fisetin/)

  Examine's fisetin page provides an independent, research-graded summary of the human and animal evidence for fisetin's effects on aging, cognition, and inflammation, with attention to the strength and limitations of the underlying studies.

  
## ConsumerLab

<!-- Author's note: consumerlab.com was searched directly using the browser tool for "Fisetin". A dedicated article exists covering fisetin and its branded forms. -->

* [Fisetin (Cognisetin & Novusetin) for Memory or Aging?](https://www.consumerlab.com/answers/can-fisetin-also-called-cognisetin-and-novusetin-really-improve-memory/fisetin-cognisetin-novusetin/)

  ConsumerLab reviews the evidence for fisetin (including the branded ingredients Cognisetin and Novusetin) for memory, aging, and blood pressure, and addresses quality, dosing, and safety considerations for consumers.

  
## Systematic Reviews

The following systematic reviews synthesize the preclinical and clinical literature on fisetin across the organ systems and disease areas most relevant to healthy aging.

* [The effects of fisetin on bone and cartilage: A systematic review.](https://pubmed.ncbi.nlm.nih.gov/36243333/) - Yamaura et al., 2022

  Synthesizes preclinical evidence that fisetin protects bone and cartilage through anti-inflammatory and senescence-clearing actions, directly relevant to the osteoarthritis and skeletal-aging trials now underway.

* [The Neuroprotective Role of Fisetin in Different Neurological Diseases: a Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/37453993/) - Jiang et al., 2023

  Reviews mechanisms by which fisetin may protect the nervous system across models of Alzheimer's, stroke, and other neurological conditions, supporting its exploration for cognitive aging.

* [Recent advances in potential of Fisetin in the management of myocardial ischemia-reperfusion injury-A systematic review.](https://pubmed.ncbi.nlm.nih.gov/35533608/) - Prem et al., 2022

  Examines fisetin's cardioprotective signaling in models of heart injury, relevant to the vascular and cardiovascular endpoints being tested in older adults.

* [Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature.](https://pubmed.ncbi.nlm.nih.gov/34836005/) - Crocetto et al., 2021

  Compares fisetin with related flavonols for anti-cancer activity, summarizing the largely preclinical evidence that underlies fisetin's speculative oncology signal.

* [Emerging Therapeutic Potential of Fisetin for Nephrotoxicity, Kidney Injury, and Nephropathy: A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/40464183/) - Mohajeri et al., 2026

  Reviews fisetin's protective effects on the kidney, an organ system relevant both to aging and to the monitoring of any long-term supplement use.

  
## Mechanism of Action

Fisetin is a flavonol (a subclass of flavonoid plant compounds) whose effects on aging are attributed to several overlapping actions:

* **Senolytic activity (clearing worn-out cells):** The action that made fisetin a longevity candidate is its apparent ability to selectively kill senescent cells — cells that have permanently stopped dividing but resist normal cell death and secrete a mix of inflammatory signals known as the senescence-associated secretory phenotype (SASP, the cocktail of inflammatory molecules released by worn-out cells). Fisetin is thought to tip these cells toward programmed cell death (apoptosis) by inhibiting the pro-survival PI3K/AKT/mTOR pathway (a central cell-growth and survival signaling cascade) and BCL-2 family survival proteins, while suppressing NF-κB (a master switch for inflammation).

* **Antioxidant and Nrf2 activation:** Fisetin directly neutralizes reactive oxygen species and activates Nrf2 (a protein that switches on the cell's own antioxidant defense genes), raising levels of protective molecules such as glutathione.

* **Anti-inflammatory signaling:** Beyond senescent-cell clearance, fisetin dampens inflammatory pathways (NF-κB, and the inflammasome) that drive the chronic low-grade inflammation of aging.

* **Sirtuin and autophagy support:** Fisetin has been reported to activate SIRT1 (a longevity-associated regulatory enzyme) and to promote autophagy (the cell's recycling of damaged components), both of which are linked to healthier aging.

Where mechanisms are contested: the senolytic effect that is robust in cell and mouse studies has not been clearly demonstrated in humans, and some researchers argue that at achievable human blood levels fisetin acts more as a general antioxidant and anti-inflammatory than as a true senescent-cell killer. Both interpretations remain on the table.

Key pharmacological properties: fisetin is a small polyphenol with **poor oral bioavailability** (a large fraction is metabolized before reaching the bloodstream) and a **short plasma half-life** (on the order of a few hours). It is **not highly selective**, engaging many molecular targets. **Tissue distribution** studies show it reaches the liver, kidney, and — to a limited degree — the brain, crossing the blood–brain barrier modestly. **Metabolism** is dominated by rapid conjugation in the gut and liver: glucuronidation by UGT enzymes (a family of liver enzymes that attach sugar groups to speed excretion) and sulfation by SULT enzymes (a family of enzymes that attach sulfate groups to speed excretion), with additional oxidative metabolism by cytochrome P450 enzymes such as CYP3A4 (a major liver enzyme that breaks down many drugs).

  
## Historical Context & Evolution

* **Original characterization:** Fisetin was first isolated in the 19th century as a natural yellow dye compound and was long studied chiefly as a dietary flavonol with antioxidant properties, alongside relatives such as quercetin.

* **Shift toward health optimization:** Interest broadened through the 2000s as laboratory work reported anti-inflammatory, neuroprotective, and anti-cancer activity in cell and animal models. The decisive turning point came in 2018, when researchers screening flavonoids for the ability to clear senescent cells identified fisetin as among the most potent, and reported that intermittent dosing extended median lifespan and improved health measures in aged mice. Those actual findings — reduced senescent-cell markers across tissues, improved physical function, and lengthened median survival — are what moved fisetin into the longevity conversation.

* **Subsequent scrutiny:** The picture has since become more nuanced rather than settled. A rigorous multi-site lifespan study (the Interventions Testing Program) found no lifespan extension from fisetin in genetically diverse mice at the doses and schedules tested. Rather than treating either result as the final word, the field currently holds both: fisetin's senolytic and healthspan signals are real in some models, while its ability to extend maximum lifespan is unproven and may depend heavily on dose, timing, formulation, and the specific aging model used. Human trials now underway are intended to resolve which of these effects, if any, translate to people.

  
## Expected Benefits

<!-- Benefits are graded by strength of the underlying evidence, weighted toward human data where it exists. For fisetin, most robust findings remain preclinical, so grades are deliberately conservative. -->

Fisetin's benefit profile is dominated by preclinical (cell and animal) evidence, with human clinical data still emerging. Grades below reflect that reality.

### Medium 🟩 🟩

#### Antioxidant & Anti-Inflammatory Activity

Fisetin reliably reduces oxidative stress and inflammatory signaling across a wide range of cell and animal models, acting through Nrf2 activation and NF-κB suppression, and small human and mechanistic studies of related flavonols support a modest anti-inflammatory effect. This is the most consistently reproduced action and the one most plausibly achievable at dietary and supplemental doses. Because chronic low-grade inflammation underlies much age-related decline, this activity is central to fisetin's rationale, though the size of the effect in humans at practical doses is not well quantified.

**Magnitude:** Preclinical studies commonly report 20–50% reductions in inflammatory markers (e.g., IL-6 and TNF-α, two proteins that drive inflammation) and oxidative-stress indices; human effect sizes are not yet reliably established.

### Low 🟩

#### Senescent Cell Clearance ⚠️ Conflicted

Fisetin's defining proposed benefit is selective clearance of senescent (worn-out) cells, robustly demonstrated in cell culture and aged mice. Human evidence is limited and mixed: some early trials report reductions in senescence markers or SASP factors, while others (including skeletal-health work) have not shown clear changes in the expected biomarkers, and measurement of senescent-cell burden in living people remains technically difficult. The mechanism is well supported preclinically, but translation to humans is unproven, which is why this benefit is graded Low despite strong animal data.

**Magnitude:** In aged mice, fisetin has reduced senescent-cell markers by roughly 25–50% in several tissues; comparable, reproducible human reductions have not been confirmed.

#### Neuroprotection & Cognitive Support

Fisetin protects neurons and preserves memory in numerous animal models of Alzheimer's disease, stroke, and normal brain aging, acting through antioxidant, anti-inflammatory, and pathway-modulating effects, and it crosses the blood–brain barrier to a limited degree. A systematic review supports a broad neuroprotective signal across neurological conditions. Human cognitive-outcome data are essentially absent, with the first dedicated Alzheimer's trials only now beginning, so the benefit remains preclinical.

**Magnitude:** Not quantified in available studies.

#### Bone & Joint Health

In animal models of accelerated aging and osteoarthritis, fisetin reduces cartilage breakdown, protects bone density, and lowers joint inflammation, and a systematic review supports these effects on bone and cartilage. Several human trials in knee osteoarthritis and skeletal health have been conducted or are underway, but published human outcomes remain preliminary and not uniformly positive. The evidence base is therefore promising but not yet established in people.

**Magnitude:** Not quantified in available studies.

#### Cardiovascular & Endothelial Function

Preclinical work shows fisetin improves the function of the vessel lining (endothelium), reduces arterial stiffness, and protects heart tissue from injury, partly by clearing senescent vascular cells and lowering inflammatory signals. Human trials in older adults targeting vascular function and arterial stiffness are active but not yet reported. The cardiovascular signal is mechanistically coherent but rests almost entirely on animal data.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Healthspan & Lifespan Extension ⚠️ Conflicted

The possibility that fisetin extends healthy lifespan is the central longevity claim, based on a landmark mouse study reporting extended median survival and improved late-life function. However, a rigorous multi-site lifespan program found no lifespan extension in genetically diverse mice, and no human data on aging outcomes exist. The two major animal results directly conflict, and the discrepancy — likely reflecting differences in mouse strain, dose, timing, and formulation — is unresolved; any human lifespan benefit is entirely hypothetical at present.

#### Anti-Cancer Activity

Fisetin shows anti-proliferative, pro-apoptotic, and anti-metastatic effects against many cancer cell lines and some animal tumor models, and systematic reviews summarize this preclinical promise for prostate, bladder, and other cancers. There are no human trials demonstrating cancer prevention or treatment benefit, and the concentrations used in laboratory studies often exceed what oral dosing achieves in blood. This benefit is mechanistic and speculative.

#### Metabolic & Glycemic Support

Animal studies suggest fisetin may improve insulin sensitivity, reduce blood-sugar excursions, and protect against complications of diabetes, plausibly through its anti-inflammatory and antioxidant actions. Human metabolic-outcome data are lacking, and the effect on people at practical doses is unknown. This remains a speculative, mechanism-based signal.

  
## Benefit-Modifying Factors

* **Genetic variation in metabolism:** Because fisetin is rapidly conjugated by UGT (sugar-attaching) and SULT (sulfate-attaching) enzymes, individuals with more active forms of these enzymes may clear it faster and achieve lower blood levels, potentially blunting benefit; this remains a theoretical consideration not yet studied clinically.

* **Baseline inflammation and senescent-cell burden:** Fisetin's rationale is strongest in people who already carry a high burden of inflammation and worn-out cells. Those with low baseline inflammation may have less room to benefit, whereas older or metabolically stressed individuals may respond more.

* **Sex-based differences:** Some rodent work shows sex-dependent responses to senolytics, with effects on cognition and metabolism differing between males and females. Whether this translates to humans is unknown, so sex-specific benefit cannot yet be predicted.

* **Pre-existing health conditions:** Individuals with age-related conditions marked by senescence (osteoarthritis, frailty, vascular dysfunction) are the populations in which benefit is being actively tested; those without such conditions have the weakest rationale for benefit.

* **Age:** Preclinical benefit is most evident when fisetin is given later in life, consistent with the accumulation of senescent cells with age. For the older end of the target audience, the rationale is correspondingly stronger, though also less tested for long-term safety.

  
## Potential Risks & Side Effects

<!-- A dedicated search of drug-reference and safety literature was performed. Fisetin has shown a clean safety profile in short human trials; most risks below are low-grade or theoretical, graded conservatively. -->

Fisetin has been well tolerated in short-term human trials, including at high senolytic doses. Most identified risks are mild, dose-related, or theoretical.

### Medium 🟥 🟥

#### Gastrointestinal Effects

The most frequently reported adverse effects with oral fisetin, particularly at the high doses used in senolytic protocols, are gastrointestinal: nausea, loose stools, and abdominal discomfort. These are generally mild, transient, and reversible on stopping, and are consistent with the effects of many concentrated polyphenol supplements. They are the practical dose-limiting issue for most users.

**Magnitude:** Reported in a minority of participants in high-dose trials; typically mild and self-limited, resolving within days of discontinuation.

### Low 🟥

#### Potential Drug Interactions (Enzyme & Transporter Inhibition)

Fisetin inhibits several drug-metabolizing cytochrome P450 enzymes (notably CYP3A4 and CYP2C9) and the drug transporter P-glycoprotein (a pump that moves drugs out of cells), which could raise blood levels of medications that depend on these systems. The clinical relevance at typical supplemental doses is uncertain but plausible, especially with narrow-therapeutic-index drugs. This risk is mechanistic but well grounded in the compound's known biochemistry, with interaction potential inferred from in vitro enzyme-inhibition data.

**Magnitude:** Not quantified in available studies.

#### Increased Bleeding Risk

Like other flavonols, fisetin can inhibit platelet aggregation and may add to the effect of anticoagulant and antiplatelet drugs, theoretically increasing bleeding risk. No serious bleeding events have been reported in the short human trials to date, but the mechanism warrants caution around surgery and in those on blood thinners.

**Magnitude:** Not quantified in available studies.

#### Blood Pressure Reduction

Fisetin has been associated with modest blood-pressure lowering, and consumer reports describe a noticeable drop in blood pressure lasting several hours after a dose in people already on antihypertensive medication. For most users this is minor, but combined with blood-pressure-lowering drugs or supplements it could cause lightheadedness or excessive lowering; anecdotal and small-study signals suggest modest, transient reductions.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Genotoxicity Concerns

At high concentrations in laboratory systems, fisetin can inhibit topoisomerase enzymes and has shown mutagenic signals in some assays, raising a theoretical concern about DNA damage with very high or chronic exposure. Whether this is relevant at achievable human blood levels is unknown, and no human harm has been observed. The concern is speculative and derived from isolated in vitro reports.

#### Endocrine / Estrogenic Modulation

Some flavonols, including fisetin, can weakly interact with estrogen signaling in laboratory models, prompting theoretical caution in hormone-sensitive conditions. There is no human evidence of clinically meaningful hormonal effects, and the basis is mechanistic and isolated.

  
## Risk-Modifying Factors

* **Genetic variation in metabolism:** Slow metabolizers (lower UGT/SULT or CYP activity, or those carrying reduced-function CYP2C9 variants) may reach higher fisetin levels and could be more prone to interaction-related effects; this is theoretical and unstudied clinically.

* **Baseline biomarker levels:** Individuals with already-low blood pressure or borderline liver or kidney markers may be more sensitive to fisetin's blood-pressure and metabolic effects and warrant closer attention.

* **Sex-based differences:** Rodent data show sex-dependent responses to senolytics; whether women and men differ in adverse-effect susceptibility to fisetin in humans is unknown.

* **Pre-existing health conditions:** Bleeding disorders, hormone-sensitive conditions, and significant liver or kidney impairment could plausibly increase risk given fisetin's antiplatelet activity, estrogenic signaling, and reliance on hepatic and renal handling.

* **Age:** Older adults — the primary group of interest — are more likely to be on multiple medications, amplifying the practical importance of the drug-interaction and blood-pressure risks even though the intrinsic side-effect profile appears mild.

  
## Key Interactions & Contraindications

* **Anticoagulants and antiplatelet drugs (warfarin, apixaban, aspirin, clopidogrel):** Additive inhibition of clotting. Severity: caution. Consequence: increased bleeding risk. Mitigation: avoid combining without medical supervision; monitor for bruising or bleeding.

* **CYP3A4 and CYP2C9 substrates (simvastatin, certain benzodiazepines, some chemotherapeutics; and CYP2C9 substrates such as phenytoin):** Fisetin's enzyme inhibition may raise their blood levels. Severity: caution to monitor. Consequence: drug accumulation and heightened side effects. Mitigation: separate timing where possible and monitor for the interacting drug's effects.

* **P-glycoprotein substrates (digoxin):** Transporter inhibition may increase absorption/levels. Severity: caution. Consequence: possible toxicity of narrow-index drugs. Mitigation: monitoring of drug levels where applicable.

* **Antihypertensive medications (ACE inhibitors [a class that relaxes blood vessels, e.g., lisinopril], calcium-channel blockers [relax blood vessels by blocking calcium entry, e.g., amlodipine], diuretics [increase urine output to lower fluid volume, e.g., hydrochlorothiazide]):** Additive blood-pressure lowering. Severity: caution. Consequence: hypotension, lightheadedness. Mitigation: monitor blood pressure, especially when starting.

* **Over-the-counter agents (aspirin, NSAIDs [non-steroidal anti-inflammatory drugs] such as ibuprofen):** Additive antiplatelet/bleeding effect and shared metabolic pathways. Severity: caution. Consequence: bleeding risk. Mitigation: caution with regular concurrent use.

* **Supplement interactions with additive effects:** Other blood-thinning or blood-pressure-lowering supplements — fish oil (omega-3s), *Ginkgo biloba*, vitamin E, garlic extract, magnesium, and coenzyme Q10 — can compound bleeding or hypotensive effects. Quercetin and curcumin share fisetin's enzyme-inhibiting and senolytic actions and may add to both benefit and interaction potential. Severity: caution. Mitigation: account for cumulative effects.

* **Populations who should avoid or use only under supervision:** Pregnant and breastfeeding individuals (no safety data); people with bleeding disorders or scheduled surgery (discontinue at least 1–2 weeks beforehand); those on narrow-therapeutic-index drugs (e.g., warfarin, digoxin); and individuals with hormone-sensitive cancers pending clinician guidance.

  
## Risk Mitigation Strategies

* **Start low and assess tolerance:** Begin at a low dose (well below high senolytic levels) and increase gradually to identify gastrointestinal tolerance before using any high-dose protocol; this directly mitigates the most common risk — nausea and loose stools.

* **Separate from and review concurrent medications:** Because fisetin can inhibit CYP3A4/CYP2C9 and P-glycoprotein, review all prescription drugs with a clinician and, where feasible, separate dosing by several hours to reduce interaction-driven drug accumulation.

* **Pause before surgery or procedures:** Discontinue fisetin at least 1–2 weeks before any planned surgery or invasive procedure to mitigate the antiplatelet-related bleeding risk.

* **Monitor blood pressure when combining with antihypertensives:** For those on blood-pressure medication or blood-pressure-lowering supplements, check blood pressure during the first weeks of use to catch excessive lowering and lightheadedness.

* **Use intermittent rather than continuous high dosing:** The senolytic strategy of short, spaced high-dose pulses (rather than daily high doses) limits total exposure and addresses the theoretical genotoxicity concern tied to chronic high-concentration exposure.

* **Choose tested products and verify liver/kidney status:** Use third-party-tested formulations and confirm baseline liver and kidney markers before high-dose use, mitigating risks tied to contaminants and to fisetin's hepatic and renal handling.

  
## Therapeutic Protocol

* **Two dominant approaches:** Practice is split between a **"hit-and-run" senolytic protocol** — short, high-dose pulses intended to clear senescent cells — popularized by aging researchers at Mayo Clinic and used in several clinical trials, and a **low-dose daily approach** used as a general antioxidant/anti-inflammatory flavonol supplement. Neither is established as superior for humans, and both are presented here without endorsement.

* **Senolytic pulse dosing:** In clinical trials the senolytic regimen typically uses approximately 20 mg/kg body weight per day for two consecutive days, repeated periodically (e.g., monthly or at longer intervals). For an 80 kg adult this is roughly 1,600 mg/day for two days.

* **Low-dose daily supplementation:** Consumer products are commonly taken at 100–500 mg per day, often as bioavailability-enhanced formulations.

* **Best time of day and with food:** Fisetin is fat-soluble and is generally taken with a meal containing fat to improve absorption; there is no strong evidence favoring a specific time of day, though taking it with the largest fat-containing meal is common practice.

* **Half-life and dosing implications:** Because fisetin has a short plasma half-life (a few hours) and poor bioavailability, single large pulses are used for the senolytic strategy on the theory that a brief high exposure is sufficient to trigger senescent-cell death, while daily low dosing relies on repeated modest exposure.

* **Single versus split dosing:** For daily use, splitting the dose (e.g., morning and evening) may sustain blood levels given the short half-life; senolytic protocols instead concentrate the dose to maximize peak exposure over the two dosing days.

* **Genetic considerations:** Variants affecting CYP and conjugating (UGT/SULT) enzymes may influence achieved blood levels and thus dose response; no pharmacogenetic dosing guidance is validated for fisetin.

* **Sex-based considerations:** Preclinical data hint at sex-dependent responses to senolytics, but no human sex-specific dosing recommendations exist.

* **Age-related considerations:** Older adults are the primary group studied; the same weight-based senolytic dosing is used, but the higher likelihood of polypharmacy in this group makes interaction review especially important.

* **Baseline biomarkers:** Baseline inflammatory markers, blood pressure, and liver/kidney function help contextualize response and safety and are commonly checked before high-dose use.

* **Pre-existing conditions:** Those with osteoarthritis, frailty, or vascular dysfunction are the conditions in which protocols are being formally tested; use outside these contexts is extrapolative.

  
## Discontinuation & Cycling

* **Not established as lifelong:** Fisetin is not a compound with a defined lifelong regimen; the senolytic rationale is inherently intermittent, and long-term continuous use has not been studied for safety or benefit.

* **No known withdrawal effects:** There are no reported withdrawal or rebound effects on stopping fisetin, consistent with its short half-life and lack of dependence-forming activity.

* **Tapering not required:** Because there is no physical dependence, no tapering protocol is needed; the compound can simply be stopped.

* **Cycling is intrinsic to the senolytic strategy:** The "hit-and-run" approach is itself a form of cycling — brief dosing separated by long drug-free intervals — based on the idea that senescent cells re-accumulate slowly, so continuous dosing is unnecessary and may be undesirable. Whether periodic cycling maintains benefit better than other schedules in humans is unproven.

  
## Sourcing and Quality

* **Source and form:** Most commercial fisetin is extracted from the *Rhus succedanea* (Japanese wax tree) or produced synthetically; it is sold as plain fisetin powder/capsules or as bioavailability-enhanced formulations. What to look for: a clearly stated fisetin content per serving and the specific form used.

* **Bioavailability-enhanced formulations:** Because plain fisetin is poorly absorbed, several products pair it with absorption enhancers (for example, a fenugreek-derived formulation marketed to increase absorption substantially, and liposomal or phospholipid-complex versions). What to look for: evidence or disclosure of the enhancement method rather than unsubstantiated absorption claims.

* **Third-party testing:** Prefer products with independent third-party testing (e.g., certificates of analysis for identity, potency, and contaminants such as heavy metals and solvents), given that polyphenol extracts vary in purity. Branded ingredients such as Cognisetin and Novusetin are examples of standardized commercial forms reviewed by independent testers.

* **Reputable suppliers:** Established supplement brands that publish certificates of analysis and use standardized or branded fisetin are preferable to unbranded bulk powders of unverified purity.

  
## Practical Considerations

* **Time to effect:** There is no validated timeline for benefit in humans. Any anti-inflammatory effect might occur over weeks; the senolytic strategy is premised on effects that would accumulate over months of intermittent dosing, but human outcome timing is unestablished.

* **Common pitfalls:** Common mistakes include using plain, poorly absorbed fisetin and expecting the dramatic effects seen in mice, extrapolating high weight-based mouse doses directly, neglecting drug-interaction review, and assuming lifespan benefit that human data do not support.

* **Regulatory status:** In the United States fisetin is sold as a dietary supplement, not an approved drug; it is not FDA-approved for treating or preventing any disease, and its use for aging is off-label and investigational.

* **Cost and accessibility:** Fisetin is inexpensive and widely available over the counter; enhanced-absorption formulations cost more but remain broadly accessible, so cost is not a major barrier.

  
## Interaction with Foundational Habits

* **Sleep:** Direction — largely indirect/none established. Fisetin is not known to disrupt or improve sleep directly. An early-stage human trial is examining whether it affects sleep quality and aging markers, but no reliable effect on sleep is currently demonstrated; there is no evidence it should be timed around sleep.

* **Nutrition:** Direction — potentiating (absorption). Fisetin is fat-soluble and better absorbed when taken with dietary fat, so pairing it with a fat-containing meal is a practical consideration. It also occurs naturally in strawberries, apples, onions, and persimmons, though food levels are far below supplemental doses. No specific diet is required, but a polyphenol-rich diet is complementary.

* **Exercise:** Direction — potentially complementary. Both exercise and fisetin are being studied together for reducing frailty and improving physical function in aging populations. There is no evidence that fisetin blunts exercise adaptations the way high-dose isolated antioxidants sometimes can, but timing relative to workouts has not been studied and no specific guidance exists.

* **Stress management:** Direction — indirect. Through anti-inflammatory and antioxidant actions fisetin may theoretically buffer some downstream effects of chronic stress, but there is no direct human evidence that it affects cortisol or the stress response, and it is not a substitute for behavioral stress management.

  
## Monitoring Protocol & Defining Success

Baseline testing before beginning fisetin — particularly before any high-dose senolytic protocol — establishes a reference for safety and for tracking the inflammatory and metabolic markers most relevant to its proposed benefits. The following labs are commonly considered.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| hs-CRP | < 1.0 mg/L | Tracks systemic inflammation, fisetin's most plausible target | High-sensitivity C-reactive protein. Conventional reference range extends to 3.0 mg/L, so this functional target is stricter. Fasting not required; avoid testing during acute illness, which transiently elevates it |
| IL-6 (interleukin-6, an inflammatory signaling protein) | < 1.8 pg/mL | Marker of the inflammatory signaling fisetin aims to reduce | Specialized test; best paired with hs-CRP for a fuller inflammation picture |
| ALT / AST | ALT < 25 U/L (men), < 20 U/L (women) | Screens liver safety given hepatic metabolism of fisetin | ALT and AST are liver enzymes. Conventional lab upper limits are roughly 40–55 U/L, so these functional targets are tighter. Fasting preferred; recheck if using high doses long-term |
| eGFR / creatinine | eGFR > 90 mL/min/1.73m² | Confirms kidney handling capacity before/during use | eGFR is estimated glomerular filtration rate, a measure of kidney function. Hydration and recent meat intake can transiently affect creatinine |
| Fasting glucose / HbA1c | Glucose 70–85 mg/dL; HbA1c < 5.4% | Contextualizes the speculative metabolic signal | HbA1c is glycated hemoglobin, a marker of average blood sugar. Conventional ranges (fasting glucose up to ~99 mg/dL; HbA1c up to 5.6%) are broader than these functional targets. Requires fasting for glucose; HbA1c reflects ~3-month average and needs no fasting |
| CBC with platelets | Platelets 150–400 ×10⁹/L | Baseline before use given antiplatelet potential | CBC is a complete blood count. Useful reference if combining with blood thinners |
| Blood pressure | < 120/80 mmHg | Captures fisetin's modest blood-pressure-lowering effect | Measure seated after rest; more relevant when on antihypertensives |

Ongoing monitoring cadence: for high-dose intermittent use, re-checking liver and kidney markers and inflammatory markers at roughly 4–8 weeks after starting and then every 6–12 months is a reasonable approach; blood pressure can be checked in the first weeks when combined with blood-pressure medication. The conventional reference range for hs-CRP extends to 3.0 mg/L, but a functional target below 1.0 mg/L is used here as an optimization goal.

Qualitative markers of response include:

* Energy levels and daytime vitality
* Joint comfort and mobility
* Physical function (e.g., walking ease and endurance)
* General inflammatory symptoms
* Cognitive clarity

  
## Emerging Research

Fisetin is the subject of an unusually active clinical-trial program spanning frailty, cancer survivorship, vascular aging, and neurodegeneration, reflecting the gap between strong preclinical data and unproven human benefit.

* **Frailty and inflammation in older adults (AFFIRM-LITE):** [NCT03675724](https://clinicaltrials.gov/study/NCT03675724) — a Mayo Clinic Phase 2 trial (40 participants) testing whether fisetin reduces blood inflammation markers and frailty in older adults; a companion trial in older women is AFFIRM ([NCT03430037](https://clinicaltrials.gov/study/NCT03430037)).

* **Vascular function in older adults:** [NCT06133634](https://clinicaltrials.gov/study/NCT06133634) — a University of Colorado Boulder Phase 1/2 trial (70 participants) evaluating fisetin's effect on endothelial function and arterial stiffness with aging.

* **Peripheral artery disease and mobility:** [NCT06399809](https://clinicaltrials.gov/study/NCT06399809) — a Northwestern University Phase 2 trial (34 participants) testing fisetin to reduce cellular senescence and improve six-minute walk distance in peripheral arterial disease.

* **Frailty in childhood-cancer survivors:** [NCT04733534](https://clinicaltrials.gov/study/NCT04733534) — a St. Jude Phase 2 trial (110 participants) measuring changes in walking speed and blood senescent-cell abundance (p16INK4A) after fisetin.

* **Skeletal health in older adults:** [NCT04313634](https://clinicaltrials.gov/study/NCT04313634) — a completed Phase 2 trial (74 participants) targeting cellular senescence to improve bone health, with a bone-resorption marker (CTX) as the primary endpoint.

* **Mild Alzheimer's disease:** [NCT07279714](https://clinicaltrials.gov/study/NCT07279714) — a Sunnybrook Phase 2 trial assessing the safety and tolerability of fisetin in mild Alzheimer's disease, among the first dedicated cognitive-outcome studies.

* **Sepsis (STOP-Sepsis):** [NCT05758246](https://clinicaltrials.gov/study/NCT05758246) — a University of Minnesota Phase 2 trial (220 participants) evaluating senolytics including fisetin to slow organ failure in sepsis, testing the anti-inflammatory rationale in acute illness.

* **Future direction — resolving the lifespan controversy:** The central open question is whether fisetin extends healthspan or lifespan in humans, given directly conflicting mouse results between the original senotherapeutic report ([Yousefzadeh et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30279143/)) and the Interventions Testing Program's null finding ([Harrison et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38041783/)). Studies clarifying optimal dose, timing, and formulation are needed to determine which effects translate.

* **Future direction — bioavailability and target engagement:** Because poor absorption may explain weak or inconsistent effects, pharmacokinetic studies such as [NCT06796374](https://clinicaltrials.gov/study/NCT06796374) (comparing fisetin kinetics in young versus old adults) and enhanced-formulation research could strengthen or weaken the case by showing whether senolytic blood levels are achievable in people.

  
## Conclusion

Fisetin is a naturally occurring plant compound, found in foods such as strawberries and apples, that has attracted attention as a possible longevity aid because of its apparent ability to clear away worn-out cells that build up with age. Its most consistent and believable effects are as an antioxidant and a calmer of inflammation. Beyond that, the evidence thins quickly: the striking results behind fisetin's reputation — clearing worn-out cells and lengthening life — come almost entirely from mice, and even there the findings conflict, with one major study reporting longer life and another rigorous program finding none. In people, benefits for brain, bone, joint, and blood-vessel aging remain plausible but largely untested, and the idea that fisetin lengthens human life is currently speculation.

On safety, short human studies show it is generally well tolerated, with mild stomach upset the main complaint and a handful of cautions around blood thinners, blood-pressure medicines, and interactions with other drugs. Overall, fisetin sits at an early and uncertain stage: interesting in how it may work, backed by strong animal data of mixed reliability, and now entering the human trials that will determine whether its promise holds. Readers weighing it will find genuine potential paired with real gaps in proof.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**